evitria AG’s Post

Antibody drug conjugates (ADC) transform the precision medicine landscape, providing better drug targeting and efficacy through monoclonal antibody-based antigen recognition. While scientists have developed several ADC to use as cancer therapies, these compounds could also serve as inspiration to create drugs for other ailments, including the senescent cell accumulation associated with aging and age-related diseases. In this webinar, Salvador Macip will explain how he developed an ADC that selectively clears senescent cells. Register today: https://ow.ly/qE1a50Sa1HL

💥 Super proud of our participating company OncoDNA, a $30 million project to fight cancer! 👊   🧬 The aim: to develop therapeutic cancer vaccines based on messenger RNA, products that are currently under development. And yes, the secret was well kept!   OncoDNA was selected by the European Commission from a list of 14 projects from five countries to support innovation in the pharmaceutical sector. This selection entitles the project to public investment of €30 million. A family of patents for these treatments has already been filed.   🚀 For our participating company, this represents a paradigm shift, since it's no longer just a question of carrying out biomarker tests to find the right treatment. The team of Jean-Pol Detiffe and Christophe Van Huffel is changing dimension and aims to become a producer of treatments that can all be customised in just a few days. A revolution! We're proud to be part of it!   Read in L'Echo article on OncoDNA's paradigm shift (link in commentary to this post) 👇   #lifesciences #cancer #health #treatment Gery Lefebvre Anne VEREECKE

Are ADCs worth a watch? They've been on the minds of dealmakers at every top pharma and it shows: ADC-related deals have increased steadily in both value and volume over the last five years. Find more data-driven insights inside the report, powered by Cortellis Intelligence and experts at Clarivate including Mike Ward John Borgman Shilpa Bali Angie Weidner and Sonia Giral López, MD PhD. #licensing #biotech #pharma #mergersandacquisitions #partnering #businessdevelopment #venturecapital #CBO #Clarivate #oncology

𝗧𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗡𝗲𝘄𝘀 𝟮𝟬𝟮𝟰 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles: 1. Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of RSV Antibody https://lnkd.in/gtAf8k-C 2. ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial https://lnkd.in/gdT388dH 3. A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology https://lnkd.in/gkBSM3Fh 4. Novo Nordisk's latest RNA deal involves $530M biobucks to sing in Korro's opera https://lnkd.in/gM86SGmw 5. Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches https://lnkd.in/gxWFTxKY P.S. Comment below with the latest pharma/biotech news you came across. #pharma #cdmo #biotech

The newest report from Clarivate is out. Download it now!

Thurs news: GSK inks 2nd neuro pact in weeks. Teva episodic migraine trial. FDA clears AZ’s Imfinzi for aggressive lung cancer. Novartis fails to block generic Entresto. Nuvig gets immune drug funding. —http://bit.ly/w28kSd

Cantargia AB's Nadunolimab, a novel IL1RAP-targeting antibody, shows promising efficacy in PDAC treatment with reduced neuropathic side effects when combined with chemotherapy, as demonstrated in the CANFOUR trial. Nadunolimab is a fully humanized monoclonal IgG1 antibody targeting the IL1 receptor accessory protein (IL1RAP). By binding to IL1RAP, nadunolimab induces antibody-dependent cellular cytotoxicity (ADCC) of IL1RAP-expressing tumor cells and inhibits tumor-promoting signals mediated by IL-1α and IL-1β within the tumor microenvironment. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's ASCO 2024 Exclusive Coverage: https://lnkd.in/gDHfK75D #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

At Lampgen Clinical Research, we are dedicated to supporting sponsors and CROs by providing highly skilled oncology CRAs to ensure their cancer clinical trials are monitored with ICH/GCP and industry standard expertise. We take pride in being the staffing firm of choice for companies conducting such critical research. The recent advancements from Nurix Therapeutics highlight the significant progress in the field of oncology. Their experimental protein degrader, NX-5948, has shown remarkable efficacy in a small study of heavily treated patients with blood cancer, achieving a 69% objective response rate. This innovative approach, which removes problematic proteins instead of merely inhibiting them, demonstrates potential benefits over existing small molecule drugs. These findings are particularly compelling given the patient population involved, including those with resistance to approved BTK inhibitors. Nurix’s degrader has shown the ability to overcome resistance mutations, offering hope to patients who have exhausted other treatment options. At Lampgen, we recognize the importance of such breakthroughs and remain committed to supporting the development and success of cutting-edge oncology trials. Together, we can make strides in the fight against cancer. #OncologyResearch #ClinicalTrials #CancerTreatment #ProteinDegraders #BTKInhibitors #ClinicalResearch #Pharma #Biotech #HealthcareInnovation #LampgenClinicalResearch #ICHGCP #CancerResearch #Hematology #DrugDevelopment 🔗 https://lnkd.in/eVdARAeG

🚨 𝐒𝐦𝐚𝐥𝐥 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐁𝐄𝐀𝐓𝐒 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 𝐢𝐧 𝐥𝐚𝐭𝐞 𝐭𝐫𝐢𝐚𝐥! Summit Therapeutics and Akeso Biopharma have made significant strides in the field of oncology with their bispecific antibody, ivonescimab, in a recent phase 3 trial conducted in China. 👉 The trial, named HARMONi-2, demonstrated ivonescimab's superiority over Keytruda (a PD-1 inhibitor) in treating non-small cell lung cancer (NSCLC), particularly in patients with PD-L1-expressing tumors. Ivonescimab showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Keytruda monotherapy. The positive results have sparked optimism among analysts and industry experts, with some calling the trial win a milestone achievement. However, the partners still face challenges in gaining approval outside of China, particularly in the U.S. Read more below 👇 #biotech #oncology #biopharma #bispecifics

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for this week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug 💊 Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer 💊 FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer 💊 GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch  #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate